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Background: To further assess the safety profile of the fixed-dose combination of indacaterol
and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of individ-
ual patient-level factors and time by integrating the patient-level safety data from the QVA149
clinical programme with relevant information from the independent indacaterol and glycopyr-
ronium safety databases.
Methods: Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were
pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of 3 month’s dura-
tion with at least two of the treatment groups: QVA149 110/50 mg, glycopyrronium 50 mg, in-
dacaterol 150 mg, placebo or tiotropium 18 mg. Overall hazard ratio (HR) was assessed between
the active treatments and placebo and in various subgroups related to severity of airways
obstruction, inhaled corticosteroid use, cardiovascular risk factors, sex, age and body mass in-
dex for death, serious cases of cardio- and cerebrovascular (CCV) events, major adverseeart and Lung Institute, Imperial College London, London SW3 6LR, UK. Tel.: þ44 07850 630745
ial.ac.uk (J.A.Wedzicha).
14.07.011
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/3.0/).
Safety of QVA149 in a pooled analysis 1499cardiovascular events (MACEs), pneumonia, COPD exacerbations requiring hospitalisation or
atrial flutter/fibrillation (AF/F).
Results: The HR for QVA149 versus placebo showed no significant increase in the overall risk for
death (HR [95% confidence interval]: 0.93 [0.34e2.54]); CCV events (0.60 [0.29e1.24]); MACE
(1.04 [0.45e2.42]); pneumonia (1.10 [0.54e2.25]); COPD exacerbations (0.60 [0.40e0.91]);
and AF/F (1.03 [0.49e2.18]). Similar results were observed for indacaterol, glycopyrronium
and tiotropium versus placebo for overall risk and in analysed subgroups.
Conclusions: There was no increase in the risk for the investigated safety endpoints for the
fixed-dose combination QVA149, and it had a comparable safety profile as its monocomponents
and tiotropium versus placebo.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Long-acting bronchodilators (b2-agonists and/or muscarinic
antagonists) are the foundation of the pharmacological
management strategy for patients with chronic obstructive
pulmonary disease (COPD) at all severity levels of the disease
(alternative choice forGOLDgroupA and first choice forGOLD
B-D) [1]. Dual bronchodilation with a long-acting b2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) is rec-
ommended for patients with a high symptomatic burden and/
or risk of exacerbations, as well as for patients who remain
symptomatic on mono-bronchodilator therapy [1,2]. It pro-
vides additional clinical benefits in terms of improving effi-
cacy and has the potential to decrease the rate of side effects
compared with increasing the dose of a mono-bronchodilator
[1] and avoiding risks such as pneumonia associated with the
use of LABA/inhaled corticosteroid (ICS) combinations [3].
The safety profile of bronchodilators in COPD remains of
prime importance [4,5]. Studies such as Towards a Revo-
lution in COPD Health (TORCH) and Understanding Long-
term Impacts on Function with Tiotropium (UPLIFT) have
provided the evidence that long-acting bronchodilators at
therapeutic doses in stable COPD do not increase risk of the
cardio- and cerebrovascular (CCV) mortality or morbidity in
patients with COPD [6,7].
The efficacy and safety of free-dose combinations of
long-acting bronchodilators such as salmeterol with tio-
tropium, formoterol with tiotropium, indacaterol with tio-
tropium, and indacaterol with glycopyrronium compared
with either one or both monocomponents have been re-
ported in several studies of 6e26 weeks of duration in pa-
tients with COPD. In these studies, the free combination
showed a similar safety profile compared with their
respective monocomponents [8e11]. QVA149 is an inhaled
once-daily (o.d.) dual bronchodilator containing a fixed-
dose combination of the LABA indacaterol maleate and
LAMA glycopyrronium bromide which along with its mono-
components, is approved in the European Union, Japan,
Canada and other countries for the maintenance treatment
of patients with COPD. The efficacy and safety of QVA149
[12e14], indacaterol [15e19] and glycopyrronium [20,21]
versus placebo and active comparators have been demon-
strated in their clinical development programmes. In the
pivotal Phase III Indacaterol and GlycopyrroNium bromide
clInical sTudiEs (IGNITE) clinical trial programme, QVA149
o.d. demonstrated an acceptable safety profile, withadverse events (AEs) and serious AEs (SAEs) being similar to
placebo, its monocomponents, tiotropium or salmeterol/
fluticasone combination (SFC) [12e14,22,23].
Here, we report a pooled analysis that was conducted to
analyse specific safety events that are of importance in
patients with COPD, so as to provide a more comprehensive
evaluation of the safety profile of QVA149. The present
analysis integrated the patient-level safety data across the
QVA149 IGNITE programme with the available relevant in-
formation from the indacaterol and glycopyrronium safety
databases so that individual components and their fixed
dose combination can be examined together along with a
standard of care, tiotropium. This analysis investigated the
impact of individual patient risk factors and duration of
exposure to study medications and provided additional as-
sessments on infrequently occurring safety endpoints.Methods
Study design and selection
All randomised clinical trials from QVA149, indacaterol and
glycopyrronium programmes were reviewed for the purpose
of this pooled analysis. The focus of the pooled analysis was
to provide information on key safety endpoints for QVA149,
and the monocomponents studies were included as a part of
its evaluation. The individual study designs of 14 included
studies for this pooled analysis are summarised in
Supplementary Appendix 1 Table A1.
This pooled analysis included data from all completed
phase III randomised clinical trials of 3 month’s duration
(study completion date as of September 30, 2012) with at
least two of the following treatment groups: QVA149 110/
50 mg o.d.; glycopyrronium 50 mg o.d.; indacaterol 150 mg
o.d.; placebo (all delivered via the Breezhaler device) or
tiotropium 18 mg o.d. (delivered via the HandiHaler device).
For studies involving indacaterol, only patients that
received the 150 mg dose were included in the analysis as
this corresponds to the equivalent indacaterol dose used in
QVA149. In order to match the fine particle dose of inda-
caterol in both the combination and the 150 mg mono-
therapy product, the dose of indacaterol in QVA149 is
110 mg and the two doses can be considered clinically
equivalent [24]. Further details on dose adjustment are
given in Supplementary Appendix 2.
1500 J.A. Wedzicha et al.The methods and the main results of the included
studies have been previously published or presented in
detail. The studies included from the indacaterol pro-
gramme were: INdacaterol: vs tiotropium to Help Achieve
New COPD treatment Excellence (INHANCE) [19,25], INda-
caterol: Toward Establishment of cliNical SuperiorITY (IN-
TENSITY) [15], INdacaterol: Double blind One yeaR Safety
Evaluation (INDORSE) [16], INdacaterol: efficacy evaLuation
usInG 150 mg doses witH COPD paTients 1 (INLIGHT1) [18],
INLIGHT2 [17], B1302 [26], and B2333 [27]; glycopyrronium
programme: GLycopyrronium bromide in COPD airWays
clinical study 1(GLOW1) [20], GLOW2 [21], and GLOW4 [28];
and QVA149 IGNITE programme: SHINE [12], SPARK [13],
ENLIGHTEN [14], and ARISE [29]. In the INTENSITY [15]
study, blinded tiotropium was used as an active compar-
ator while INHANCE [19], GLOW2 [21], SHINE [12], SPARK
[13] and ARISE [29] studies had open-label tiotropium as an
active comparator. All included studies were approved by
institutional review boards and ethics committees at
participating centres, and were conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice.
All the patients provided written informed consent.
Patients/study population
The patients’ inclusion and exclusion criteria in this
pooled analysis were similar across all studies. The pro-
tocols of the included studies allowed patients with stable
co-morbid cardiovascular conditions to be screened and
included in studies at the discretion and judgment of the
investigator.
The studies enrolled men and women aged 40 years
with moderate-to-severe COPD (Stage II or III according toTable 1 Safety population by study and treatment (number of
Study Treatment
Duration
QVA149
110/50 mg
Indac
150 m
Indacaterol
INHANCE [19,25] 26 weeks 0 272
INDORSE [16] 52 weeks 0 144
INLIGHT1 [18] 12 weeks 0 211
INLIGHT2 [17] 26 weeks 0 330
INTENSITY [15] 12 weeks 0 794
B2333 [27] 26 weeks 0 187
B1302 [26] 12 weeks 0 114
Glycopyrronium
GLOW1 [20] 26 weeks 0 0
GLOW2 [21] 52 weeks 0 0
GLOW4 [28] 52 weeks 0 0
QVA149
SHINE [12] 26 weeks 474 476
SPARK [13] 64-76 weeks 729 0
ENLIGHTEN [14] 52 weeks 225 0
ARISE [29] 52 weeks 119 0
Total 1547 2528
INDORSE, INdacaterol: Double blind One yeaR Safety Evaluation; IN
treatment Excellence; INLIGHT1, INdacaterol: efficacy evaLuation usI
Toward Establishment of cliNical SuperiorITY; GLOW, GLycopyrronium
a All tiotropium treatment arms were open-label, except for INTENthe GOLD 2005 and 2008 criteria; post-bronchodilator
forced expiratory volume in 1 s [FEV1] of 30% and <80%
of the predicted normal; post-bronchodilator FEV1 to
forced vital capacity (FVC) ratio of <0.70 at screening),
with the exception of the SPARK study that had patients
with severe-to-very severe COPD (Stage IIIeIV according to
the GOLD 2008 criteria; post-bronchodilator FEV1 50%
predicted) and a documented exacerbation history in the
last year [13]. Patients were current or ex-smokers with a
smoking history of 10 pack-years (20 pack-years in B1302
[26], INHANCE [19,25], INDORSE [16], INLIGHT1 [18], and
INLIGHT2 [17]).
Patients with conditions such as ischaemic heart dis-
ease, left ventricular failure, history of myocardial infarc-
tion (MI) or arrhythmia (excluding chronic stable atrial
flutter/fibrillation [AF/F]) were not specifically excluded
from the studies, unless these cardiovascular conditions
were regarded as to affect the patient’s safety, compliance
or ability to complete the study as per the investigator’s
discretion.
In most of the studies, the key exclusion criteria were:
a history of the long QT syndrome or a prolonged QTc in-
terval at screening (>450 ms for males and females), a
history of asthma or a clinically abnormal electrocardio-
gram (ECG) that could potentially place patients at risk if
enrolled into the study as per the investigator’s
discretion.
Evaluations and outcome measures
The present analysis focused on infrequently occurring
safety endpoints that included the risk of death (all-cause
mortality), CCV events, major adverse cardiovascularpatients).
aterol
g
Glycopyrronium
50 mg
Tiotropium
18 mga
Placebo
0 415 294
0 0 124
0 0 205
0 0 335
0 799 0
0 0 186
0 0 117
550 0 267
525 267 268
123 40 0
473 480 232
740 737 0
0 0 113
0 39 0
2411 2777 2141
HANCE, INdacaterol: vs tiotropium to Help Achieve New COPD
nG 150 mg doses witH COPD paTients 1; INTENSITY, INdacaterol:
bromide in COPD airWays clinical study.
SITY study.
Safety of QVA149 in a pooled analysis 1501events (MACEs), pneumonia, COPD exacerbations requiring
hospitalisation and atrial flutter/fibrillation. MACEs were
categorised as non-fatal MI, unstable angina, non-fatal
stroke, heart failure requiring hospitalisation and coro-
nary revascularisation. The details of the terms are
included in the Supplementary Appendix 2.
The overall hazard ratio (HR) was assessed between
placebo and active therapy arms that included o.d.
QVA149, indacaterol, glycopyrronium or tiotropium by
incorporating the relevant covariates that may have impact
on the safety outcome.
In addition, it was assessed whether there was any evi-
dence that the HR of QVA149 or any other drug versus
placebo changes over time in various subgroups based onTable 2 Demographics and baseline patient characteristics acr
Parameter QVA149 110/50 mg
(n Z 1547)
Indacaterol 15
(n Z 2528)
Mean (SD) age
in years
63.8 (8.51) 63.8 (8.90)
Age (years)
<65 818 (52.9) 1298 (51.3)
65 to <75 554 (35.8) 927 (36.7)
75 175 (11.3) 303 (12.0)
Sex
Male 1206 (78.0) 1799 (71.2)
Female 341 (22.0) 729 (28.8)
Race
Caucasian 1093 (70.7) 1894 (74.9)
Black 5 (0.3) 42 (1.7)
Asian 395 (25.5) 522 (20.7)
Other 54 (3.5) 70 (2.8)
BMI (kg/m2)
30.0 1289 (83.3) 1968 (77.9)
>30.0 258 (16.7) 560 (22.2)
Mean (SD) BMI (kg/m2) 25.3 (5.32) 26.2 (5.52)
Severity of COPD
Moderate 539 (34.8) 1511 (59.8)
Severe or very severe 1007 (65.1) 1017 (40.2)
ICS use 948 (61.3) 1152 (45.6)
Smoking history
Ex-smoker 943 (61.0) 1460 (57.8)
Current smoker 604 (39.0) 1068 (42.3)
Number of CV risk factorsa
0e2 1072 (69.3) 1122 (44.4)
3 475 (30.7) 1405 (55.6)
History of diabetes mellitus 151 (9.8) 254 (10.1)
CCV conditionb 157 (10.2) 302 (12.0)
Hyperlipidaemia 376 (24.3) 602 (23.8)
Hypertension 700 (45.2) 1027 (40.6)
Values are n (%) unless otherwise indicated. BMI, body mass index; C
monary disease; CV, cardiovascular; ICS, inhaled corticosteroid; Med
deviation.
Missing values not included.
a CV risk factors include: 1. presence of CCV history/condition at b
hyperlipidaemia at baseline; 4. presence of history of diabetes mellitu
65 years; 7. current smoker.
b CCV condition determined based on the following pre-defined s
infarction (20,000,047, narrow), other ischaemic heart disease (20,0
and haemorrhagic cerebrovascular conditions (20,000,063 and 20,000,the following baseline factors: severity (moderate [FEV1
>50% and <80% of the predicted normal] and severe or very
severe based on GOLD 2008); ICS use (yes or no); cardio-
vascular (CV) risk factors (0e2 or 3); sex (male or female);
age group (<65 or 65 years) and body mass index (BMI;
<30 or 30 kg/m2).
CV risk factors were determined based on the following
baseline conditions: presence of CCV history/condition at
baseline based on the pre-defined Standardised Medical
Queries (SMQs) including MI, ischaemic heart disease, car-
diac failure, ischaemic and haemorrhagic cerebrovascular
conditions, and cardiac arrhythmias; presence of hyper-
tension at baseline; presence of hyperlipidaemia at base-
line; presence of history of diabetes mellitus (type II);oss all studies (safety population).
0 mg Glycopyrronium 50 mg
(n Z 2411)
Tiotropium 18 mg
(n Z 2777)
Placebo
(n Z 2141)
63.9 (8.82) 63.8 (8.33) 64.0 (8.93)
1235 (51.2) 1467 (52.8) 1082 (50.5)
900 (37.3) 1025 (36.9) 810 (37.8)
276 (11.4) 285 (10.3) 249 (11.6)
1821 (75.5) 1963 (70.7) 1551 (72.4)
590 (24.5) 814 (29.3) 590 (27.6)
1725 (71.6) 2277 (82.0) 1456 (68.0)
33 (1.4) 42 (1.5) 33 (1.5)
573 (23.8) 360 (13.0) 601 (28.1)
80 (3.3) 98 (3.5) 51 (2.4)
1903 (78.9) 2143 (77.2) 1699 (79.4)
507 (21.0) 633 (22.8) 441 (20.6)
25.9 (5.82) 26.3 (5.67) 25.8 (5.69)
1030 (42.7) 1250 (45.0) 1288 (60.2)
1380 (57.2) 1526 (55.0) 852 (39.8)
1458 (60.5) 1587 (57.2) 919 (42.9)
1481 (61.4) 1639 (59.0) 1259 (58.8)
930 (38.6) 1138 (41.0) 882 (41.2)
1282 (53.2) 1449 (52.2) 961 (44.9)
1129 (46.8) 1328 (47.8) 1180 (55.1)
283 (11.7) 282 (10.2) 220 (10.3)
273 (11.3) 314 (11.3) 253 (11.8)
593 (24.6) 725 (26.1) 514 (24.0)
1079 (44.8) 1221 (44.0) 877 (41.0)
CV, cardio- and cerebrovascular; COPD, chronic obstructive pul-
DRA, Medical Dictionary for Regulatory Activities; SD, standard
aseline; 2. presence of hypertension at baseline; 3. presence of
s; 5. presence of obesity at baseline (i.e., BMI >30 kg/m2); 6. age
tandardised MedDRA queries (SMQs) search criteria: myocardial
00,168, narrow), cardiac failure (20,000,004, narrow), ischaemic
064, narrow), and cardiac arrhythmia terms (20,000,050, broad).
Figure 1 Forest plot of HRs for QVA149 (n [ 1547) and tiotropium (n [ 2777) versus placebo (n [ 2141) (a) Death and
serious CCV events BMI, body mass index; CCV, cardio- and cerebrovascular; CI, confidence interval; CV, cardiovascular; HR,
hazard ratio; ICS, inhaled corticosteroid (b) MACE and pneumonia BMI, body mass index; CI, confidence interval; CV, cardiovas-
cular; HR, hazard ratio; ICS, inhaled corticosteroid; MACE, major adverse cardiovascular event; MACE events included non-
Safety of QVA149 in a pooled analysis 1503presence of obesity (i.e., BMI >30 kg/m2); age 65 years;
or current smoker.
MACEs included non-adjudicated events from the inda-
caterol and glycopyrronium studies and adjudicated events
from the QVA149 programme (performed by an indepen-
dent adjudication committee). Adjudicated MACEs, when
available or treatment-emergent SAEs as reported by in-
vestigators or identified using pre-defined search criteria,
within 30 days of the last dose, were included in the
analysis.
Statistical analysis
All analyses were based on the safety population defined as
all randomised patients who received at least one dose of
the study medication. The exposure data were collected on
electronic case report forms. Serious events of interest
were included only if the start date was within 30 days of
the last study dose. As studies were completed at various
times, AEs were coded with different MedDRA versions. For
the pooled analysis database, lower-level term codes were
mapped to the latest MedDRA version (version 15.0). Data
were analysed using a Cox proportional hazard model, with
treatment, study, COPD severity, ICS use and the number of
CV risk factors as fixed covariates.
The subgroup analyses of the time to first event were
also performed using a Cox regression model with factors
for treatment, study, baseline COPD severity (GOLD 2008),
baseline ICS use, number of CV risk factors and the sub-
group by treatment interaction term. For the subgroups of
sex, age and BMI, the model also included the factor for
subgroup.
The estimated HRs (active treatment versus placebo)
along with its 95% confidence interval (CI) was calculated
from the model and was used to interpret the results. For
AF/F, only adjudicated data from QVA149 studiesdSHINE
[12], SPARK [13], ENLIGHTEN [14], and ARISE [29] and gly-
copyrronium studiesdGLOW1 [20], GLOW2 [21], and
GLOW4 [28] were available for use (adjudicated by an in-
dependent committee). Non-adjudicated data from inda-
caterol studies were used in the analysis, as adjudicated
data were not available.
The model was based on the assumptions that all pa-
tients share an equivalent baseline hazard function over
time, and the model accounts for the treatment and the
impact of different studies, COPD severity, ICS use status
and CV risk factors on the hazard.
Results
Patient characteristics
The analysis included safety data from 11,404 patients,
with 1547 receiving QVA149; 2528 receiving indacaterol;adjudicated events from the indacaterol and glycopyrronium studie
exacerbation requiring hospitalisation and Atrial flutter/fibrillati
chronic obstructive pulmonary disease; CV, cardiovascular; HR, h
adjudicated.2411 receiving glycopyrronium; 2777 receiving tiotropium;
and 2141 receiving placebo (Table 1). Baseline patient de-
mographics and other clinical characteristics were compa-
rable across all the treatment groups, with the notable
exception that more patients in the QVA149 group versus
the other treatment groups had severe or very severe COPD
(65.1% versus 39.8%e57.2%), due to the inclusion of data
from the SPARK study. There was also a higher percentage
of patients who used ICS at baseline (61.3% versus 42.9%e
60.5%) in the QVA149 treatment arm while fewer patients
on QVA149 had 2 CV risk factors at study entry (30.7%
versus 46.8%e55.6%). The tiotropium group had more
Caucasian patients (82.0% versus 68.0%e74.9%) and less
Asian patients (13.0% versus 20.7%e28.1%) than the other
treatment groups (Table 2).
Safety
The mean exposure was highest in the QVA149 group
(333.2 days) compared with its monocomponents indaca-
terol (138.4 days) and glycopyrronium (283.1 days), tio-
tropium (228.8 days) and placebo (178.6 days), due to the
inclusion of the SPARK study that had a treatment duration
of 64e76 weeks. A higher proportion of patients in the
QVA149 group (83.6%) were treated for more than 6
months compared with the other treatment groups
(30.6%e75.7%), with 51.7% of the patients in the QVA149
group being treated for more than 12 months
(Supplementary Appendix 3 Table A2).
The HRs for QVA149 versus placebo and tiotropium
versus placebo showed no significant increase in the overall
risk for death, serious CCV events, MACEs, pneumonia or
AF/F (Fig. 1). The overall risk of COPD exacerbation was
significantly lower for QVA149 versus placebo (HR: 0.60;
95% CI: 0.40e0.91), tiotropium versus placebo (HR: 0.49;
95% CI: 0.32e0.74; Fig. 1c) and glycopyrronium versus
placebo (HR: 0.61; 95% CI: 0.41e0.89) while it was non-
significant for indacaterol versus placebo (HR: 0.82; 95%
CI: 0.47e1.42; Supplementary Appendix 4 Fig. A1c).
There was no significant increase in the risk for QVA149
or tiotropium versus placebo for any of the analysed CV
safety endpoints for all subgroups related to severity of
COPD (GOLD 2008), baseline ICS use, CV risk factors, sex,
age or BMI (Fig. 1aec). Overall, the HR values for QVA149
versus placebo were comparable to those observed with
tiotropium versus placebo subgroups in a cross-comparison
manner.
The risk of COPD exacerbation was significantly lower for
QVA149 versus placebo in the subgroups (moderate COPD,
baseline ICS use, female, age <65 years, BMI <30 kg/m2).
Similar results were seen with those observed with tio-
tropium versus placebo and glycopyrronium versus placebo
(Fig. 1c and Supplementary Appendix 4 Fig. A1c). However,
as mentioned earlier, tiotropium was open label in 5 of 6
studies.s and adjudicated events from the QVA149 programme (c) COPD
on (AF/F) BMI, body mass index; CI, confidence interval; COPD,
azard ratio; ICS, inhaled corticosteroid; All AF/F events were
1504 J.A. Wedzicha et al.The risk of serious CCV events was significantly lower in
patients with baseline ICS use for QVA149 versus placebo
(HR: 0.35; 95% CI: 0.14e0.86). The risk of serious CCV
events was also shown significantly lower in patients with
3 CV risk factors for tiotropium (HR: 0.45; 95% CI:
0.22e0.96, Fig. 1a) and glycopyrronium versus placebo (HR:
0.47; 95% CI: 0.23e0.99, Supplementary Appendix 4
Fig. A1a), with similar risk with QVA149 versus placebo
(HR: 0.67; 95% CI: 0.29e1.53, Fig. 1a).
The HR values in some of the subgroups investigated for
all treatments versus placebo had wide 95% CI around the
outcomes (Fig. 1 and Supplementary Appendix 4 Fig. A1),
which is likely due to low number of events and/or low
number of patients with in these subgroups or variation in
the data. Most importantly, none of the differences in the
HRs suggested significantly increased risk.
There was also no significant increase in the overall risk
and in the subgroups for death, serious CCV events, MACEs,
pneumonia, COPD exacerbations requiring hospitalisation
or AF/F for indacaterol versus placebo and glycopyrronium
versus placebo except for MACE in patients with BMI
30 kg/m2 for glycopyrronium versus placebo where HR
was in favour of placebo (HR: 3.03; 95%CI: 1.02e8.97)
(Supplementary Appendix 4 Fig. A1).Discussion
The current pooled analysis included data from 11,404
patients from 14 randomised clinical trials across multiple
safety databases. It was observed that the fixed-dose
combination QVA149 indirectly compared with its mono-
components (indacaterol and glycopyrronium), tiotropium
and versus treatment with placebo did not increase the
risk of death (all-cause mortality), serious cases of car-
dio- and cerebrovascular (CCV) events, major adverse
cardiovascular events (MACEs), pneumonia, COPD exac-
erbations requiring hospitalisation or atrial flutter/fibril-
lation (AF/F) events overall and in a diverse range of
subgroups.
The technique of pooled analysis of randomised
controlled trials, in which data is pooled from trials having
at least one intervention in common with another, has been
used recently for analysing data, as it allows comparison of
multiple interventions that have not been evaluated
directly against each other [30]. The analysis of pooled data
may also help to identify safety events that might occur at
low frequencies in the individual data sets.
The results observed with QVA149 versus placebo in the
current analysis did not show any increase in risk for any of
the investigated safety points. The results were consistent
with the QVA149 cardiac safety data from Phase III studies,
and confirmed that no significant cardiovascular safety or
mortality concerns were observed in these studies with
QVA149 [12,13,22].
CCV diseases have been reported to occur at increased
rates in patients with COPD, perhaps because of shared risk
factors such as smoking [31]. Rates of incident cardiovas-
cular events are also increased in these patients [32].
In the current analysis, there was no significant increase
in the risk for MACEs and other cardiovascular safety end
points (serious CCV and AF/F) with QVA149 versus placebodespite the inclusion of more patients with severe and very
severe COPD in the QVA149 group (65.1%). QVA149 also did
not increase the risk of death versus placebo, and the re-
sults were comparable to those observed with tiotropium
versus placebo. The results of the pooled analysis suggests
that the risk of cardiovascular events for QVA149 versus
placebo was comparable between older patients (age 65
years) and younger patients (age < 65 years); patients with
moderate COPD and those with severe COPD; patients with
high CV risk (CV risk factor  3) and low risk (CV risk factor
0e2); and in obese patients (BMI  30 kg/m2) or otherwise
(BMI < 30 kg/m2). These data provide some level of
assurance of the cardiovascular safety of QVA149 in higher
risk patients.
The results observed for tiotropium versus placebo in the
current analysis were consistent with those observed pre-
viously in the UPLIFT study [7,33] and other reported meta-
analyses of tiotropium 18 mg administered via the Handi-
Haler device for the risk of all-cause mortality [34,35] and
major cardiovascular events versus placebo [36].
Clinically important subgroups of patients based on at-
tributes such as age, sex, co-morbid condition or some
combination of these attributes can influence the level of
responsiveness to the treatment of COPD. Hence, it is
important to analyse the effect of the treatment in the
subgroups [37].There was no significant increase in risk with
QVA149, indacaterol or glycopyrronium versus placebo for
most of the subgroups related to severity, baseline ICS use,
CV risk factors, sex, age or BMI for any of the investigated
safety end points. The results were comparable to the tio-
tropium versus placebo data in a cross-comparison manner.
The results for indacaterol versus placebo were also
consistent with those of other reported meta-analysis and
pooled studies of indacaterol 150 mg in terms of mortality
and exacerbations, and did not show any significant in-
crease in the overall risk for any of the investigated sub-
groups [38,39].
In the current pooled analysis, QVA149 was not associ-
ated with an increase in the overall risk of pneumonia
compared with placebo (HR: 1.10; 95% CI: 0.54e2.25) and
in the subgroup related to baseline ICS use (HR: 1.05; 95%
CI: 0.43e2.56). This provides additional evidence that the
fixed-dose LABA/LAMA combinations, such as QVA149,
could be a useful treatment option for symptomatic pa-
tients with COPD, as it demonstrated similar safety profile
compared with its monocomponents.
Potential limitations of this pooled analysis include the
fact that the trials included in the pooled analysis were not
specifically designed and powered to evaluate CV events
and patients with high CV risks were excluded from the
studies. Real-life long-term safety studies with more pa-
tients and longer-term follow-up are required to analyse
the safety of drugs in such patients. Events were recorded
only during the duration of the studies (until 30 days of last
treatment) and vital status follow up was not performed in
most of the studies. Further, tiotropium was open-label in
all studies included in the pooled analysis, except for IN-
TENSITY, where blinded tiotropium was used. Also, the
number of GOLD IV (very severe) patients was limited in the
analysis (SPARK study only).
However, the strength of the current pooled analysis lies
in the fact that the safety data have been pooled from 12
Safety of QVA149 in a pooled analysis 1505published and 2 reported randomised clinical trials, with
more than 11,000 patients with COPD being included in the
analysis. The trials included in the analysis had similar in-
clusion and exclusion criteria, with the exception of the
SPARK study, and there was no evidence of clinical or sta-
tistical heterogeneity between the trials. Different sub-
groups based on the severity, baseline ICS use, CV risk
factors, sex, age and BMI were explored, which reflect the
overall risk factors in a general population of COPD. The
statistical analysis was conducted using the Cox propor-
tional hazard model, which incorporated the important
covariates such as study, baseline COPD severity, baseline
ICS use, number of CV risk factors. Further, the adverse
event reporting was complete for all the trials despite some
being of shorter duration and extended to 30 days after the
last study medication. Adjudicated data were used for the
analysis, except for atrial fibrillation data for indacaterol
where the non-adjudicated data were included in the
analysis.Conclusions
In this pooled analysis across multiple safety databases that
included data from 11,404 patients, the incidence of
deaths, serious CCV events, MACEs, pneumonia, exacerba-
tions requiring hospitalisation and atrial flutter/fibrillation
was comparable between QVA149 and placebo, with no
increase in the overall risk being observed for any of the
investigated safety endpoints for any of the drugs versus
placebo.
There was no increase in infrequent AEs versus placebo
for the fixed-dose combination QVA149, and additionally its
safety profile was comparable to its monocomponents
(indacaterol and glycopyrronium) and tiotropium. These
data provide further reassurance that the use of dual
bronchodilation may be of clinical benefit to patients with
COPD, without a safety penalty.Role of funding source
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